162 related articles for article (PubMed ID: 31228461)
1. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization.
Luis de Redín I; Boiero C; Recalde S; Agüeros M; Allemandi D; Llabot JM; García-Layana A; Irache JM
Exp Eye Res; 2019 Aug; 185():107697. PubMed ID: 31228461
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model.
Sahan B; Ciftci F; Eyuboglu S; Yaba A; Yilmaz B; Yalvac BI
Cornea; 2019 Sep; 38(9):1161-1168. PubMed ID: 31180924
[TBL] [Abstract][Full Text] [Related]
3. Human serum albumin nanoparticles for ocular delivery of bevacizumab.
Luis de Redín I; Boiero C; Martínez-Ohárriz MC; Agüeros M; Ramos R; Peñuelas I; Allemandi D; Llabot JM; Irache JM
Int J Pharm; 2018 Apr; 541(1-2):214-223. PubMed ID: 29481946
[TBL] [Abstract][Full Text] [Related]
4. Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.
Lee JE; Kim KL; Kim D; Yeo Y; Han H; Kim MG; Kim SH; Kim H; Jeong JH; Suh W
Int J Nanomedicine; 2017; 12():4813-4822. PubMed ID: 28740387
[TBL] [Abstract][Full Text] [Related]
5. Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats.
Li Z; Yao L; Li J; Zhang W; Wu X; Liu Y; Lin M; Su W; Li Y; Liang D
Int J Nanomedicine; 2012; 7():1163-73. PubMed ID: 22419865
[TBL] [Abstract][Full Text] [Related]
6. Salubrinal Ameliorates Inflammation and Neovascularization via the Caspase 3/Enos Signaling in an Alkaline-Induced Rat Corneal Neovascularization Model.
Ozge G; Karaca U; Savran M; Usta G; Gulle K; Sevimli M; Cankara FN; Asci H
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837524
[No Abstract] [Full Text] [Related]
7. Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.
Menguy T; Briaux A; Jeunesse E; Giustiniani J; Calcei A; Guyon T; Mizrahi J; Haegel H; Duong V; Soler V; Brousset P; Bensussan A; Raymond Letron I; Le Bouteiller P
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2687-2698. PubMed ID: 29860455
[TBL] [Abstract][Full Text] [Related]
8. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
10. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.
Kim YC; Grossniklaus HE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2014 Sep; 55(11):7376-86. PubMed ID: 25212779
[TBL] [Abstract][Full Text] [Related]
11. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits.
Kim RY; Chung SK; Kim MS; Ra H
Cornea; 2016 Dec; 35(12):1615-1620. PubMed ID: 27684458
[TBL] [Abstract][Full Text] [Related]
12. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
14. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
[TBL] [Abstract][Full Text] [Related]
15. Regression of corneal neovascularization: Adiponectin versus bevacizumab eye drops.
Baradaran-Rafii A; Ashnagar A; Heidari Keshel S; Jabbehdari S; Baradaran-Rafii G
Eur J Ophthalmol; 2021 Jan; 31(1):78-82. PubMed ID: 31523981
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247
[TBL] [Abstract][Full Text] [Related]
17. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.
Yildirim H; Aydemir O; Balbaba M; Özercan İH; İlhan N
Cutan Ocul Toxicol; 2020 Sep; 39(3):223-228. PubMed ID: 32338080
[TBL] [Abstract][Full Text] [Related]
19. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
20. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
